Presentation is loading. Please wait.

Presentation is loading. Please wait.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Published byMyles Douglas Modified over 5 years ago

Similar presentations

Presentation on theme: "PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models"— Presentation transcript:

1 Fig. 4. PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models.
PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models. (A to C) Mice bearing NCI-H358 tumors were treated with PBS, AZD4785, or CTRL ASO at 50 mpk 5× weekly for 4 weeks. (A) KRAS, DUSP4, and DUSP6 mRNA were measured in NCI-H358 tumors at the end of the study by qRT-PCR. The expression was normalized to 18S ribosomal RNA (rRNA) and expressed relative to PBS. Data are shown as individual tumor data, treatment group geometric mean, and SE. (B) AZD4785 significantly inhibited tumor growth of NCI-H358 tumors compared to PBS (TGI, 72%; P = ) and CTRL ASO (TGI, 75%; P = 0.001). Data are shown as the geometric mean of the tumor volume and SE. (C) Surrogate endpoint survival graphs for the NCI-H358 study. Data are shown as the percentage of remaining animals with tumors <4× the initial starting volume in each treatment group. (D to F) Mice bearing NCI-H1944 tumors were treated with PBS, AZD4785, or CTRL ASO at 50 mpk 5× weekly for 7 weeks. (D) KRAS, DUSP4, and DUSP6 mRNA were measured in NCI-H1944 tumors at the end of the study by qRT-PCR. The expression was normalized to ACTIN and presented relative to PBS. Data are shown as individual tumor data, treatment group mean, and SE. (E) AZD4785 significantly inhibited tumor growth compared to PBS (TGI, 80%; P = 0.001) and CTRL ASO (TGI, 67%; P < 0.001). Data are shown as the geometric mean of the tumor volume and SE. (F) Surrogate endpoint survival graphs for the NCI-H1944 study. Data are shown as the percentage of remaining animals with tumors <4× the initial starting volume in each treatment group. Sarah J. Ross et al., Sci Transl Med 2017;9:eaal5253 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Download ppt "PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models"

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Three different types of transfer functions with a codomain of [0,1].

Three different types of transfer functions with a codomain of [0,1].
Group data during free walking between sessions 1 and 16.

Group data during free walking between sessions 1 and 16.
Human cells produce type I and III IFNs upon Af stimulation.

Human cells produce type I and III IFNs upon Af stimulation.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.
Fig. 5 Correlation of RNA expression and protein abundance.

Fig. 5 Correlation of RNA expression and protein abundance.
BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.

BAP1 deficiency results in thymic atrophy and loss of thymocyte populations. BAP1 deficiency results in thymic atrophy and loss of thymocyte populations.
Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria. Inhibiting or altering.

Inhibiting or altering the timing of microbial antigen encounter results in inflammatory T cell responses against gut bacteria. Inhibiting or altering.
Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.
Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.
Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)
Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.
Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.
Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Similar presentations

Ads by Google